TVM

EQS-News: TVM CAPITAL LIFE SCIENCE TO PARTICIPATE IN LSI USA ’24 EMERGING MEDTECH SUMMIT 2024

Retrieved on: 
Wednesday, April 10, 2024
Radiation, Thrombosis, Partner (business rank), Infection, Intelligence, TVM, Risk, General partnership, Patient, Eye injury, Standard of care, AI, Workflow, Investment, LSI, Phlebitis, Eli Lilly and Company, Vector, Therapy, FDA, Physician, Health, PFC, Medical imaging

Munich, Germany and Montreal, Quebec, Canada (March 13, 2024) – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.

Key Points: 
  • Munich, Germany and Montreal, Quebec, Canada (March 13, 2024) – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.
  • The conference will take place March 18-22, 2024, in Dana Point, California, USA.
  • "Medtech innovation continues to be at the forefront of healthcare advancement, driving transformative changes in patient care, operational efficiency and cost reduction.
  • As part of our commercial-stage medical technologies investment strategy, TVM seeks breakthrough solutions that align with emerging trends and could redefine the standard of care.

TVM Capital Life Science to Participate in LSI USA ’24 Emerging Medtech Summit 2024

Retrieved on: 
Wednesday, March 13, 2024
Radiation, Thrombosis, Partner (business rank), Infection, Intelligence, TVM, Risk, General partnership, Patient, Eye injury, Standard of care, AI, Workflow, Investment, Medtech, LSI, Phlebitis, Eli Lilly and Company, Vector, Therapy, FDA, Physician, Health, PFC, Medical imaging

MUNICH, Germany and MONTREAL, March 13, 2024 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.

Key Points: 
  • MUNICH, Germany and MONTREAL, March 13, 2024 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.
  • The conference will take place March 18-22, 2024, in Dana Point, California, USA.
  • “Medtech innovation continues to be at the forefront of healthcare advancement, driving transformative changes in patient care, operational efficiency and cost reduction.
  • As part of our commercial-stage medical technologies investment strategy, TVM seeks breakthrough solutions that align with emerging trends and could redefine the standard of care.

TRON Network Recognized in Reports by Messari and Reflexivity Research

Retrieved on: 
Tuesday, February 6, 2024
TRON, Research, TVL, Growth, Blockchain, USDT, Social media, TVM, Cryptocurrency

Geneva, Switzerland / February 05, 2024 / - The TRON network has been analyzed in reports by Messari and Reflexivity Research, highlighting its significant role and technological advancements in the blockchain industry.

Key Points: 
  • Geneva, Switzerland / February 05, 2024 / - The TRON network has been analyzed in reports by Messari and Reflexivity Research, highlighting its significant role and technological advancements in the blockchain industry.
  • Messari’s State of TRON research highlights the continued growth of USDT on the TRON blockchain, revealing an 11% growth in Q4.
  • Reflexivity Research ’s report explores the TRON network’s active accounts.
  • For detailed analyses and findings, readers are encouraged to refer to the full reports by Messari and Reflexivity Research.

EQS-News: TVM CAPITAL LIFE SCIENCE CO-LEADS $16 MILLION SERIES A FINANCING ROUND FOR VEKTOR MEDICAL TO REVOLUTIONIZE ARRHYTHMIA CARE

Retrieved on: 
Tuesday, February 6, 2024
Atrial fibrillation, Vektor, Extended play, Patient, FDA, Investment, ECG, Arrhythmia, Physician, General partnership, Vector, TVM

Munich, Germany and Montreal, Quebec, Canada, February 6, 2024 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced a $16 million Series A financing for Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology.

Key Points: 
  • Munich, Germany and Montreal, Quebec, Canada, February 6, 2024 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced a $16 million Series A financing for Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology.
  • The proceeds will be used to support the commercialization of vMap®, Vektor’s AI-based arrhythmia analysis tool, which is transforming how electrophysiologists (EPs) approach ablation procedures.
  • Dr. Luc Marengère, Managing Partner at TVM, will join the Vektor Medical Board of Directors, and Dr. Sascha Berger, General Partner at TVM, will serve as a Board Observer.
  • Dr. Luc Marengère, Managing Partner at TVM Capital Life Science, said: “Changing the standard of care demands a unique and transformative approach.

TVM Capital Life Science Co-Leads $16 Million Series A Financing Round for Vektor Medical to Revolutionize Arrhythmia Care

Retrieved on: 
Tuesday, February 6, 2024
Atrial fibrillation, Vektor, Extended play, Patient, FDA, Investment, ECG, Arrhythmia, Physician, General partnership, Vector, TVM

MUNICH, Germany and MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced a $16 million Series A financing for Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology.

Key Points: 
  • MUNICH, Germany and MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced a $16 million Series A financing for Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology.
  • Dr. Luc Marengère, Managing Partner at TVM, will join the Vektor Medical Board of Directors, and Dr. Sascha Berger, General Partner at TVM, will serve as a Board Observer.
  • Vektor’s vMap is the only FDA-cleared, non-invasive AI-based solution for arrhythmia localization and analysis, seamlessly leveraging only a 12-lead ECG.
  • Dr. Luc Marengère, Managing Partner at TVM Capital Life Science, said: “Changing the standard of care demands a unique and transformative approach.

Vektor Medical Secures $16 Million Series A Funding

Retrieved on: 
Monday, February 5, 2024
Health, Medical Devices, Hospitals, Health Technology, General Health, Cardiology, Biotechnology, TVM, Vektor, Extended play, Patient, FDA, Medicine, ECG, Arrhythmia, Physician, Vector, Atrial fibrillation

Vektor Medical , a pioneer in non-invasive, AI-based arrhythmia analysis technology, today announced a $16 million Series A investment co-led by Solas BioVentures and TVM Capital Life Science.

Key Points: 
  • Vektor Medical , a pioneer in non-invasive, AI-based arrhythmia analysis technology, today announced a $16 million Series A investment co-led by Solas BioVentures and TVM Capital Life Science.
  • This funding underscores investor confidence in Vektor’s vision and ability to successfully execute its mission to revolutionize arrhythmia care.
  • “The medical community is being confronted with the necessity for change.
  • With an increasing atrial fibrillation (AF) patient population, outcomes must be improved while also enhancing procedure efficiency,” said Rob Krummen, CEO of Vektor Medical.

EQS-News: TVM CAPITAL LIFE SCIENCE ANNOUNCES €8 MILLION INVESTMENT IN MYO TO REVOLUTIONIZE ELDERLY CARE VIA INNOVATIVE, EASY-TO-USE APP

Retrieved on: 
Monday, February 5, 2024
Myo, TVM, Patient, Digital, Marketing, Investment, Documentation, Communication, General partnership, Health, Jasper, Pharmacy, Health insurance

TVM CAPITAL LIFE SCIENCE ANNOUNCES €8 MILLION INVESTMENT IN MYO TO REVOLUTIONIZE ELDERLY CARE VIA INNOVATIVE, EASY-TO-USE APP

Key Points: 
  • TVM CAPITAL LIFE SCIENCE ANNOUNCES €8 MILLION INVESTMENT IN MYO TO REVOLUTIONIZE ELDERLY CARE VIA INNOVATIVE, EASY-TO-USE APP
    The issuer is solely responsible for the content of this announcement.
  • TVM CAPITAL LIFE SCIENCE ANNOUNCES €8 MILLION INVESTMENT IN MYO TO REVOLUTIONIZE ELDERLY CARE VIA INNOVATIVE, EASY-TO-USE APP
    Munich, Germany and Montreal, Quebec, Canada (January 31, 2024) – TVM Capital Life Science (“TVM”), a leading transatlantic venture capital firm focused on investments in life sciences innovation, today announced the closing of a Series A financing round for Myosotis GmbH (“myo”), a pioneering Berlin-based digital healthcare startup.
  • Dr. Sascha Berger, General Partner, and Stefan Fischer, Managing Partner (Finance) of TVM, will join the myo Board of Directors.
  • Dr. Sascha Berger, General Partner of TVM Capital Life Science, commented: “At TVM, we are committed to advancing healthcare innovations that address unmet needs.

TVM Capital Life Science Announces €8 Million Investment in myo to Revolutionize Elderly Care via Innovative, Easy-to-Use App

Retrieved on: 
Wednesday, January 31, 2024
Myo, Patient, Digital, Marketing, Investment, Documentation, Communication, General partnership, Health, Jasper, Pharmacy, TVM

The proceeds will be used to further grow the business in the DACH region as well as in the UK.

Key Points: 
  • The proceeds will be used to further grow the business in the DACH region as well as in the UK.
  • Dr. Sascha Berger, General Partner, and Stefan Fischer, Managing Partner (Finance) of TVM, will join the myo Board of Directors.
  • The company’s communication app enables care facilities, families and service providers to communicate with each other easily, quickly and digitally.
  • Dr. Sascha Berger, General Partner of TVM Capital Life Science, commented: “At TVM, we are committed to advancing healthcare innovations that address unmet needs.

TNS Provides Payment Processing Platform for Scheidt & Bachmann Ticket Machines Across UK and Ireland Transport Networks

Retrieved on: 
Thursday, October 12, 2023
Professional Services, Rail, Technology, Transport, Software, Electronic Commerce, Fintech, Nexus, Cloud, Multimedia, TVM, VISA, Transaction Network Services, PCI, Scheidt & Bachmann Ticket XPress, Great Western Railway, Network operations center, CP, API, Mastercard, Gateway, Govia Thameslink Railway, TNS, Omnichannel, Cryptocurrency, Payment card, Iarnród Éireann, Scheidt, Luas, American Express

Scheidt & Bachmann Fare Collection Systems has chosen Transaction Network Services (TNS) to provide payment gateway services for approximately 4,000 ticket vending machines (TVMs), which serve the UK and Ireland’s transport networks and handle over 90 million transactions per year.

Key Points: 
  • Scheidt & Bachmann Fare Collection Systems has chosen Transaction Network Services (TNS) to provide payment gateway services for approximately 4,000 ticket vending machines (TVMs), which serve the UK and Ireland’s transport networks and handle over 90 million transactions per year.
  • View the full release here: https://www.businesswire.com/news/home/20231012130042/en/
    (L-R) Matthew Thomas - Managing Director UK & Ireland, TNS Payments Market and Ken Cameron - Managing Director Fare Collection Systems at Scheidt & Bachmann UK.
  • “We’re pleased to have partnered with TNS for our UK and Ireland payment processing needs,” said Ken Cameron, Managing Director Fare Collection Systems at Scheidt & Bachmann UK.
  • “TNS has been a trusted, global partner of Scheidt & Bachmann for many years, working closely with the parking division of the business,” said Matthew Thomas, Managing Director of UK and Ireland, TNS Payments Market .

Alpha Transform Holdings Announces Investment in Everscale Protocol (EVER)

Retrieved on: 
Wednesday, September 20, 2023
REMP, TVM, POS, Reliability, TPS, ATH, Dapp, Architecture, Growth, Blockchain, Ecosystem, Cryptocurrency

With this investment, Alpha Transform Holdings will stimulate network development with integrations of additional partner wallets, new exchange listings, further project implementations and other network-building endeavors.

Key Points: 
  • With this investment, Alpha Transform Holdings will stimulate network development with integrations of additional partner wallets, new exchange listings, further project implementations and other network-building endeavors.
  • "This investment means a great deal to the ongoing development of the Everscale network and ecosystem.
  • This collaboration represents an exciting opportunity for Alpha Transform Holdings to support Everscale as it expands and scales,” stated Enzo Villani, CEO/Founder, Alpha Transform Holdings.
  • Everscale aims to become a hub for high-load applications with real use cases with the potential to radically transform modern finance.